The Precision Bridge: MRI-Guided CED And Translatable NHP Models For CNS Drug Delivery

📅 Wednesday April 29, 2026

Register Now

MRI-Guided CED and Translatable NHP Models for CNS Drug Delivery

Accurate delivery of therapeutics to specific regions of the brain remains a central challenge in central nervous system (CNS) drug development. Limitations associated with the blood–brain barrier (BBB), as well as constraints in verifying target engagement, contribute to uncertainty during clinical translation.

This webinar introduces an integrated approach combining intraoperative MRI (iMRI)-guided navigation with Convection-Enhanced Delivery (CED) in non-human primate (NHP) models, enabling real-time visualization and controlled intracranial administration.

The session will also present imaging-guided dosing strategies and discuss how consistency between preclinical and clinical workflows may support more informed decision-making in CNS drug development.

Key Topics

Challenges in CNS drug delivery and target verification
MRI-guided (vs. MRI-verified) intracranial procedures
Principles and applications of Convection-Enhanced Delivery (CED)
Integration of navigation systems for trajectory planning and real-time monitoring
Imaging-guided dosing strategies in NHP models
Considerations for improving translational continuity from preclinical to clinical stages

Who Should Attend?

This webinar may be relevant to professionals working in:

Preclinical pharmacology and translational research
CNS drug development in pharmaceutical and biotechnology organizations
Gene therapy, oligonucleotide, or biologics development
Pharmacokinetics, biodistribution, or toxicology studies
Neuroscience research and clinical translation

Speakers

David S. Wong
BD Manager, Asia Pacific

Mr. Wong is responsible for business development activities across Asia-Pacific, supporting the adoption of MRI-guided neurosurgical platforms and translational applications of intracranial delivery technologies.

Message Presenter

James Song
General Manager PRISYS Biotech

As General Manager of Prisys Biotech, James Song leverages 20 years of experience in NHP pharmacology and disease modeling to accelerate the transition from lab to clinic. He is a specialist in navigating the complexities of translational medicine, with a proven track record in managing high-value asset restructuring and forging strategic international alliances. Under his leadership, Prisys has strengthened its global footprint through sophisticated laboratory infrastructure, unique NHP models, and integrated NHP breeding operations.

Message Presenter

Join this webinar to gain a structured understanding of current approaches to CNS drug delivery, including imaging-guided techniques and methods for evaluating biodistribution and delivery performance.

Project > Webinar